Delivery Order #75N93019F00131

HHS Awards $21.87M to Battelle for Efficacy Testing of Filovirus Vaccines

This contract, classified as a delivery order under a cost-plus-fixed-fee arrangement, was awarded to Battelle Memorial Institute by the Department of Health and Human Services (HHS). Battelle specializes in scientific research and development, particularly in healthcare solutions and biological threat reduction. The awarded contract focuses on immunogenicity and efficacy testing of medical countermeasures, specifically vaccines and biologics against BSL-4 pathogens in Non-Human Primates (NHPs). This effort is significant as it enhances the agency's ability to prepare for infectious disease outbreaks and national health emergencies. The contracting process was open to competition, and the contract is not designated as a small business set-aside. The contract holds a total potential value of $21,870,389.00, with a current total value of $7,725,601.00. The period of performance began on July 30, 2019, and extends through December 31, 2025. Key subcontractors include the University of Texas Medical Branch at Galveston, conducting immunogenicity and efficacy assessments for candidate filovirus vaccines, and the Trustees of Boston University, providing preclinical vaccine testing services.

Description

BATTELLE MEMORIAL INSTITUTE; IMMUNOGENICITY AND EFFICACY TESTING OF MEDICAL COUNTERMEASURES (VACCINES AND OTHER BIOLOGICS) AGAINST BSL-4 PATHOGENS IN NHPS; TO 2

View original record